L-carnitine is obtained by reacting 3-dehydrocarnitine or one of its salts, in aqueous medium, simultaneously with: (a) carnitine dehydrogenase, (b) a coenzyme utilized by carnitine dehydrogenase for reducing dehydrocarnitine, preferably nicotinamide adenine dinucleotide, and (c) a reducing agent for the coenzyme, the coenzyme (b) and carnitine dehydrogenase being preferably used in catalytic amount.
Water-soluble polyesters useful in the preparation of bioerodible hydrogels are described. The polyesters are formed by condensing three monomers: a first monomer which is either an unsaturated aliphatic or cycloaliphatic dicarboxylic acid or an unsaturated aliphatic or cycloaliphatic diol; a second monomer which is a water-soluble polyglycol; and a third monomer which is a dicarboxylic acid having an electron-withdrawing group placed vicinally to a carbonyl group of the acid. Water-soluble polyesters with molecular weights ranging from about 5000 to about 30,000 are disclosed.
PROPARGYL ALCOHOL, PROCESS FOR PRODUCING INTERMEDIATE THEREFOR, AND USE THEREOF
申请人:SHOWA DENKO K.K.
公开号:EP1186586A1
公开(公告)日:2002-03-13
Processes are provided for producing propargyl alcohol in an industrially advantageous manner. One of the processes comprises reaction of 1,2,3-trichloropropane with 3 equivalents or more of an alkali compound to produce propargyl alcohol. The other process comprises (1) a first step of reaction of 2,3-dichloro-1-propanol with an amine to produce chloroallyl alcohol, and (2) a second step of reaction of the chloroallyl alcohol obtained in the above step (1) with an alkali compound to produce propargyl alcohol.
A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation.
[wherein R1 represents hydrogen, R2 represents optionally substituted phenyl, etc., R3 represents optionally substituted C6-10 aryl, etc.]
由以下通式(1)代表的化合物或其盐具有丝氨酸蛋白酶抑制活性,尤其是对凝血因子 VIIa 具有极佳的抑制活性。该化合物或其盐类可作为治疗和/或预防血栓形成相关疾病的药物。
[其中 R1 代表氢,R2 代表任选取代的苯基等,R3 代表任选取代的 C6-10 芳基等。]
Composition for resist patterning and method for forming pattern using same
申请人:AZ Electronic Materials (Luxembourg) S.a.r.l.
公开号:US10191380B2
公开(公告)日:2019-01-29
[Problem]
To provide a composition capable of improving surface roughness of resist patterns, and also to provide a pattern formation method employing the composition.
[Solution]
The present invention provides a composition containing a particular nitrogen-containing compound, an anionic surfactant having a sulfo group, and water; and also provides a pattern formation method containing a step of applying the composition to a resist pattern beforehand developed and dried.